Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for…
Nektar Therapeutics and Bristol Myers Squibb, on Thursday, announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in…
Read More...
Read More...